Literature DB >> 3610043

Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam.

G Bakti, H U Fisch, G Karlaganis, C Minder, J Bircher.   

Abstract

Mechanisms responsible for disproportional sedation resulting from triazolam administration to patients with cirrhosis were investigated. Ordinary sedative doses (0.25 mg) were given p.o. to 8 cirrhotics and 18 controls. Plasma concentrations of unbound drug were assessed by capillary gas chromatography and equilibrium dialysis. Median apparent oral clearances of unbound triazolam were 14.8 ml per min per kg in cirrhotics and 23.9 ml per min per kg in controls (p less than 0.01). Clearances were significantly correlated with severity of liver disease as assessed by the aminopyrine breath test (Rs = 0.77, n = 17, p less than 0.001). At a time when plasma concentrations of unbound triazolam were the same in both groups, i.e., 2.25 hr after dosing, flicker sensitivity at 5 Hz which was used as an index of CNS performance was impaired by a factor of 3.2 in cirrhotics and 1.4 in controls (p less than 0.01 for group difference). Performance was also significantly lower in cirrhotics with the digit symbol substitution test (p less than 0.05). It is concluded that, in patients with cirrhosis, disproportional sedation after benzodiazepine administration may be due not only to impaired drug elimination, but also to hypersensitivity of the brain.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3610043     DOI: 10.1002/hep.1840070403

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  35 in total

Review 1.  Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management.

Authors:  T Gerber; H Schomerus
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

2.  Fulminant hepatic failure associated with triazolam.

Authors:  Tatsuo Kanda; Osamu Yokosuka; Keiichi Fujiwara; Hiromitsu Saisho; Hidetoshi Shiga; Shigeto Oda; Keiko Okuda; Yasuhiko Sugawara; Masatoshi Makuuchi; Hiroyuki Hirasawa
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

Review 3.  Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure?

Authors:  E A Jones; A S Basile
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 4.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 5.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 6.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 7.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 8.  The pharmacologic management of insomnia in patients with HIV.

Authors:  Toma S Omonuwa; Harold W Goforth; Xavier Preud'homme; Andrew D Krystal
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

9.  Excessive motor impairment two hours after triazolam in the elderly.

Authors:  H U Fisch; G Baktir; G Karlaganis; C Minder; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 10.  Neuropsychological aspects of liver disease and its treatment.

Authors:  R E O'Carroll
Journal:  Neurochem Res       Date:  2007-10-24       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.